[go: up one dir, main page]

PE20080125A1 - Metodo para modular la funcion de la vejiga - Google Patents

Metodo para modular la funcion de la vejiga

Info

Publication number
PE20080125A1
PE20080125A1 PE2007000318A PE2007000318A PE20080125A1 PE 20080125 A1 PE20080125 A1 PE 20080125A1 PE 2007000318 A PE2007000318 A PE 2007000318A PE 2007000318 A PE2007000318 A PE 2007000318A PE 20080125 A1 PE20080125 A1 PE 20080125A1
Authority
PE
Peru
Prior art keywords
function
quinoline
bromo
halogen
bladder
Prior art date
Application number
PE2007000318A
Other languages
English (en)
Inventor
William Jacobson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38474526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080125A1 publication Critical patent/PE20080125A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE ---- ES UN ENLACE SIMPLE O DOBLE; n ES 1-2; m ES 0-1; R1 Y R2 SON CADA UNO HALOGENO, -CN, -R; R ES H, ALQUILO C1-C6; R3 Y R4 JUNTOS FORMAN, CON EL CARBONO AL QUE ESTAN UNIDOS, UN ANILLO DE 4 A 8 MIEMBROS SUSTITUIDO CON 1-3 GRUPOS SELECCIONADOS DE HALOGENO, -R, OR; R5 Y R6 SON -R. SON COMPUESTOS PREFERIDOS: 2-BROMO-4,5,6,7,9,9a,10,11,12,12a - DECAHIDROCICLOPENTA[c][1,4]DIAZEPINO[6,7,1-ij]QUINOLINA; 2-BROMO-4,5,6,7,9,9a,10,11,12,13,14,14a-DODECAHIDROCICLOPENTA[c][1,4]DIAZEPINO[6,7,1-ij]QUINOLINA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS ACTUAN EN LA MODULACION DE LA FUNCION VESICAL SIENDO UTILES EN EL MANTENIMIENTO DEL CONTROL DE LA VEJIGA O EL TRATAMIENTO DE INCONTINENCIA URINARIA
PE2007000318A 2006-03-24 2007-03-23 Metodo para modular la funcion de la vejiga PE20080125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78545106P 2006-03-24 2006-03-24

Publications (1)

Publication Number Publication Date
PE20080125A1 true PE20080125A1 (es) 2008-04-07

Family

ID=38474526

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000318A PE20080125A1 (es) 2006-03-24 2007-03-23 Metodo para modular la funcion de la vejiga

Country Status (15)

Country Link
US (2) US20070225274A1 (es)
EP (1) EP1998782A2 (es)
KR (1) KR20080107430A (es)
CN (1) CN101405005A (es)
AR (1) AR060324A1 (es)
AU (1) AU2007230891A1 (es)
BR (1) BRPI0709164A2 (es)
CA (1) CA2645099A1 (es)
CL (1) CL2007000774A1 (es)
IL (1) IL193841A0 (es)
MX (1) MX2008012105A (es)
PA (1) PA8720701A1 (es)
PE (1) PE20080125A1 (es)
TW (1) TW200806298A (es)
WO (1) WO2007112073A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
US20070225277A1 (en) * 2006-03-24 2007-09-27 Wyeth Treatment of pain
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
EP2421870B1 (en) 2009-04-23 2016-03-09 AbbVie Inc. Modulators of 5-ht receptors and methods of use thereof
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
MX2011012479A (es) 2009-05-22 2012-03-06 Abbott Lab Moduladores de los receptores 5-ht y metodos de uso de los mismos.
WO2011146089A1 (en) * 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
UA116216C2 (uk) 2012-09-14 2018-02-26 Еббві Дойчланд Гмбх Унд Ко. Кг Трициклічні хінолінові і хіноксалінові похідні
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
CN103204858A (zh) * 2013-03-20 2013-07-17 广州科瑞生物技术有限公司 基于酒石酸拆分合成工艺制备新型手性抗焦虑症药物
EP3116873B1 (en) 2014-03-14 2018-02-28 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a cyclic radical
EP3116874B1 (en) 2014-03-14 2018-02-28 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a substituted alkyl radical
WO2017089458A1 (en) 2015-11-25 2017-06-01 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
WO2021019350A1 (en) * 2019-07-30 2021-02-04 Cellix Bio Private Limited Composition and methods for the treatment of anal and rectal disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CO5210925A1 (es) * 1998-11-17 2002-10-30 Novartis Ag Derivados de diamino nitroguanidina tetrasustituidos
MXPA01011905A (es) * 1999-05-21 2004-03-19 Biovitrum Ab Compuestos novedosos, su uso y preparacion.
AU5216801A (en) * 2000-03-16 2001-09-24 Hoffmann La Roche Carboxylic acid derivatives as ip antagonists
AR031201A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AU2002239463A1 (en) * 2000-11-03 2002-06-03 Wyeth Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
US6849619B2 (en) * 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
RU2003121304A (ru) * 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US8685924B2 (en) * 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
PE20070549A1 (es) * 2005-10-17 2007-06-15 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
PE20080126A1 (es) * 2006-03-24 2008-04-07 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.

Also Published As

Publication number Publication date
AU2007230891A1 (en) 2007-10-04
WO2007112073A3 (en) 2007-11-29
MX2008012105A (es) 2008-10-03
IL193841A0 (en) 2009-09-22
CN101405005A (zh) 2009-04-08
CA2645099A1 (en) 2007-10-04
PA8720701A1 (es) 2008-11-19
US20070225274A1 (en) 2007-09-27
AR060324A1 (es) 2008-06-11
TW200806298A (en) 2008-02-01
US20090281091A1 (en) 2009-11-12
WO2007112073A2 (en) 2007-10-04
KR20080107430A (ko) 2008-12-10
BRPI0709164A2 (pt) 2011-06-28
EP1998782A2 (en) 2008-12-10
CL2007000774A1 (es) 2008-03-07

Similar Documents

Publication Publication Date Title
PE20080125A1 (es) Metodo para modular la funcion de la vejiga
PE20080126A1 (es) Metodos para tratar trastornos cognitivos y otros afines
AR043060A1 (es) Derivados de xantina, su preparacion y su uso en la preparacion de medicamentos
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
PE20080010A1 (es) Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
EP2586780A4 (en) 2-ARYL-IMIDAZO- [1,2-A] -PYRIDINE-3-ACETAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
MXPA06002880A (es) Derivados 1,1,1-trifluoro-4-fenil-4-metil-2-(1h-pirrolo `2,3-cipiridin-2-ilmetil) pentan-2-ol y compuestos relacionados como ligandos glucorticoides para el tratamiento de enfermedades inflamatorias y diabetes.
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
UY31614A1 (es) Nuevos compuestos de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol y métodos de uso de los mismos.
AR022283A1 (es) Aminas substituidas de espirofuropiridinas novedosas utiles en terapia
ES2101258T3 (es) Derivados de pirazol; procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
PE20160588A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR010896A1 (es) Heterociclos biciclicos disustituidos y sus sales fisiologicamente compatibles, su utilizacion, procedimiento para su preparacion, medicamentos que los contienen y procedimiento para la preparacion de dichos medicamentos.
DOP2007000018A (es) Moduladores de indol sulfonamida de receptores de progesterona
PE20231106A1 (es) Inhibidores de apol1 y metodos para usar los mismos
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
PE20000467A1 (es) Derivado de indol util como inhibidor de serotonina
PE20220904A1 (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
AR073158A1 (es) Metodo y composicion para modular el crecimiento de celulas madre
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
PE20091182A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-CARBOXAMIDAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
MX339692B (es) Moduladores de los receptores 5-ht y metodos de uso de los mismos.
PE20020905A1 (es) Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip

Legal Events

Date Code Title Description
FD Application declared void or lapsed